Viewing nowDiamicron MR (Gliclazide)
Gliclazide 30mg
Tablet · Prescription medication
Korea Servier Co., Ltd.

MFDS item code 200806454 · Approved 2008.06.12 · Insurance code 676300040
Treatment of type 2 diabetes mellitus inadequately controlled with diet and exercise
This medication is used for patients with type 2 diabetes who have difficulty controlling their blood sugar through diet and exercise alone. It helps effectively lower blood glucose, contributing to preventing the progression of diabetes and reducing the risk of complications. Continuous use facilitates blood sugar management and helps maintain a healthy lifestyle. When used appropriately according to the patient's condition, it significantly aids in blood sugar control, hence it is used for the treatment of diabetes.
Adults: Administer 30~120mg of gliclazide orally once daily in the morning, adjusting the dose according to blood glucose levels. It is recommended to swallow this medicine whole without crushing or chewing it. If a dose is missed, do not increase the dose the following day. When taken with other blood glucose-lowering agents, the dose should be adjusted according to the individual patient's metabolic response (blood glucose, glycated hemoglobin). * Initial dose The recommended initial dose is 30mg once daily. - If blood glucose control is satisfactory, maintain this dose. - If blood glucose control is unsatisfactory, the dose may be gradually increased to 60, 90, and 120mg once daily at intervals of at least 1 month. If blood glucose has not decreased after 15 days of treatment, increase the dose from the end of the second week of treatment. Do not exceed 120mg once daily. * Switching from gliclazide 80mg to gliclazide modified-release tablets 30mg: In patients stabilized on gliclazide 80mg, administer the medicine according to the principle that “gliclazide 80mg = gliclazide modified-release tablets 30mg.” * Switching from another oral blood glucose-lowering agent to gliclazide modified-release tablets 30mg: This medicine (modified-release tablets 30mg) may replace another oral blood glucose-lowering agent. When switching, take into account the dose and half-life of the previous blood glucose-lowering agent. In general, switching can be done without any transitional drug-free period. Start this medicine at 30mg once daily and gradually increase the dose according to each patient's metabolic response, as described under “Initial dose.” In patients switching from a sulfonylurea blood glucose-lowering agent with a long half-life, a drug-free period of several days is required to prevent the risk of hypoglycemia due to the additive effects of the two medicines. * Concomitant use with other oral blood glucose-lowering agents This medicine may be used in combination with biguanides, α-glucosidase inhibitors, or insulin. In patients whose condition is not adequately controlled with this medicine, concomitant treatment with insulin may be initiated under close medical supervision. * Elderly patients This medicine may be prescribed using the same administration method as in patients 65 years of age or younger. * Patients with renal impairment In patients with mild or moderate renal impairment, this medicine may be prescribed using the same administration method as in patients with normal renal function, with careful patient monitoring. * Patients at risk of hypoglycemia - Poor nutritional status or malnutrition - Severe or decompensated endocrine disorders (anterior pituitary insufficiency, hypothyroidism, corticotropin insufficiency) - Discontinuation of long-term and/or high-dose corticosteroid therapy - Severe vascular disease (severe coronary heart disease, severe carotid artery disease, disseminated vascular disease) → It is recommended to initiate treatment at the minimum dose of 30mg once daily.
This medication is a sulfonylurea, which can cause hypoglycemia; therefore, blood glucose levels must be closely monitored while taking it. It should not be administered to certain patients such as those with diabetic ketoacidosis, type 1 diabetes, severe liver or kidney dysfunction, severe infections, and patients undergoing surgery, nor should it be taken by pregnant or breastfeeding women. During the use of this medication, a decrease in food intake or gastrointestinal disturbances such as vomiting or diarrhea can increase the risk of hypoglycemia, so caution is necessary. Elderly patients or those with compromised kidney or liver function, as well as patients with poor nutrition or irregular eating habits, should also use it cautiously. Symptoms of hypoglycemia may include lethargy, headache, tremors, confusion, drowsiness, and in severe cases may lead to altered consciousness, seizures, or coma, hence immediate consultation with medical personnel is required. This medication may interact with other drugs; therefore, blood glucose fluctuations should be closely observed when taken concurrently with miconazole, alcohol, certain anti-inflammatory drugs, antihypertensives, antibiotics, etc. Women who are pregnant or planning to become pregnant are advised to use insulin therapy instead, and breastfeeding women should also avoid using this medication. Safety for children has not been established; hence, its use is not recommended. Overdose may lead to hypoglycemia, and if symptoms appear, immediate glucose intake or emergency measures should be taken. During the initial dosing phase, it is important to be well informed about hypoglycemia symptoms and to be cautious when driving or operating machinery. Store this medication out of reach of children, and do not transfer it to another container.
Hypoglycemia, weakness, intense hunger, tremors, headache, altered perception, excitement, decreased concentration, aggression, nausea, vomiting, lethargy, sleep disturbances, decreased cognitive ability and slow response, depression, confusion, visual and language impairments, aphasia, incomplete paralysis, dizziness, loss of self-control, delirium, shallow breathing, bradycardia, drowsiness, altered consciousness, convulsions, coma, sweating, palpitations, cold and clammy skin, anxiety, tachycardia, hypertension, angina, deep vein thrombosis, thrombocytopenia, anemia, leukopenia, granulocytopenia, agranulocytosis, elevated AST, elevated ALT, elevated ALP, liver dysfunction, hepatitis, jaundice, dyspepsia accompanied by vomiting, abdominal pain, diarrhea, constipation, itching, rash, urticaria, angioedema, erythema, large blister rash, measles-like papular rash, vesicular reaction, eosinophilia, drug rash, transient visual impairment
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius.
White oblong modified-release tablet
500 tablets/bottle, 60 tablets (30 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowGliclazide 30mg
Tablet · Prescription medication
Korea Servier Co., Ltd.

Gliclazide 80mg
Tablet · Prescription medication
(Samchundang Pharmaceuticals Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
(Shinil Pharmaceutical Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
(Samnam Pharmaceutical Co., Ltd.)
Gliclazide 80mg
Tablet · Prescription medication
SK Chemicals Co., Ltd.

Gliclazide 80mg
Tablet · Prescription medication
Teragen Itex Co., Ltd.

Gliclazide 60mg
Tablet · Prescription medication
Korea Servier Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.